Stay updated with breaking news from Alannah nugent. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/CNW/ - To shine a spotlight on the pressure and loneliness that many Canadians face during the holiday season, Wellness Together Canada has partnered with. ....
KEYTRUDA ® is an anti-PD-1 therapy that works by helping increase the ability of the body s immune system to help detect and fight tumour cells. 1 An estimated 26,900 Canadians were diagnosed with colorectal cancer in 2020, with an average of 73 Canadians diagnosed daily. 2 KIRKLAND, QC, March 8, 2021 /CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Health Canada has approved KEYTRUDA ® (pembrolizumab), Merck s anti-PD-1 therapy, for the first-line treatment, as monotherapy, for adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC). 3 This approval offers a new first-line treatment option for patients with MSI-H/dMMR metastatic colorectal cancer, said Dr. Ron Burkes, Professor of Medicine, University of Toronto and Medical Oncologist, Mount Sinai Hospital. ....
Learn more about Acute Myeloid Leukemia and ONUREG (CNW Group/Bristol Myers Squibb Canada Co.) AML is a heterogeneous clonal disorder characterized by immature myeloid cell proliferation and bone marrow failure, and is the most common form of acute leukemia in adults, accounting for approximately 80 per cent of adult cases. 2,3,4 An estimated 40-60 per cent of patients aged 60 years and older and 60-80 per cent of patients under 60 years old will obtain complete remission through induction chemotherapy (IC); however, 50 per cent will relapse within a year. 5,6 Once a relapse occurs, long-term survival averages at six months. 7 In 2015, an estimated 1,235 Canadians were diagnosed with AML and the overall incidence rate in Canada is 3.46/100,000 people. ....